IPA's Subsidiary BioStrand Secures Second
VLAIO Research Grant
IPA subsidiary BioStrand receives grant to expand
LENSai platform by linking HYFTs™ with 3D protein structure and
function
Diepenbeek, (Belgium), May 9, 2022 - IPA (IMMUNOPRECISE
ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA's subsidiary
Biostrand, a Belgian end-to-end multi-omics analysis platform
provider, has received a €460,000 round of grant funding
from VLAIO (Flanders Innovation &
Entrepreneurship), the research
fund of the Flemish regional government in Belgium.
Conditionally awarded in January this year, BioStrand recently
satisfied the remaining criteria for the award, which follows an
original grant from VLAIO of €235,000 in 2020. Commenting on the
latest grant, Dr. Ingrid Brands, General Manager and co-founder of
BioStrand, stated, "Thus far, our patented HYFT™-based methodology
has been applied predominantly to streamline analysis at the
syntactic level and combines sequence information with natural
language processing. Using the presence, occurrence, and
distribution of HYFT™ patterns, the focus has been on analysis and
integration of sequence-based 'syntactical' information. We are now
extending the methodology to combine syntactical and structural
information and to expand our services portfolio with HYFT™-based
structural and functional modelling functionalities. By linking
HYFTs™ with the 3D structure (and function) of proteins and
expanding platform capabilities for AI discovery, we will be able
to support an even wider array of applications, including assay
development, biomarker discovery, and computer-aided drug
design."
The strategic objective driving this HYFT™-based synthesis of
syntactical and structural information is to extend BioStrand's
technology to encompass the structure of proteins. A key advantage
of this blended approach is the detection of protein sequences with
similar structures (and function) but without high sequence
similarity (distant homologs). A primary application for this
approach will be in protein structure prediction, with a particular
first focus on antibodies as well as G protein coupled receptors
(GPCRs). This will be extended to cover protein-protein interaction
prediction (PPI) at a later stage.
BioStrand is also working on an AI Discovery platform that will
leverage advanced AI techniques to facilitate integrated protein
structure and function analysis. Combined with existing R&R and
Variant Analyzer modules, natural language analysis capabilities
and the HYFT™-based unified syntactical plus structural
methodology, BioStrand's AI discovery platform will empower
researchers to fully analyse their data and gain insights across
the entire analysis pipeline, from raw sequencing data to
biologically relevant aspects such as diagnostics and drug
discovery.
The expansion of BioStrand's omics platform with these advanced
functionalities is crucial to become an ambitious market player and
position BioStrand as a one-stop-shop for omics analysis," said Dr.
Brands. "We believe that integrating sequence and 3D structure
analysis in combination with natural language processing will
revolutionize protein structure and function prediction and boost
developments in biotechnology and precision
medicine. Providing a powerful, integrated, and user-friendly
data analysis platform for life sciences researchers is our
contribution to ramping up the effectiveness of R&D cycles and
enabling the real-time analysis of actionable patient data that
will bring precision medicine to the next level. It also takes us
one step further in our mission to create a truly effective omics
data analysis solution."
The Company also announces the departure of Stefan Lang, Chief
Business officer of IPA, effective immediately, and wishes him the
best in his future endeavors.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotherapeutic,
innovation-powered company that supports its business partners in
their quest to discover and develop novel antibodies against a
broad range of target classes and diseases. The Company offers a
hybrid of services and programs with advanced platforms and
technologies — dynamic scientists and business advisors — to
optimize antibody discovery and development, against rare and/or
challenging epitopes. For further information, visit www.immunoprecise.com.
Investor contact:
Email: investors@immunoprecise.com
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified
using words such as "potential", "plans", "expects" or "does not
expect", "is expected", "estimates", "intends", "anticipates" or
"does not anticipate", or "believes", or variations of such words
and phrases or state that certain actions, events or results "may",
"could", "would", "might" or "will" be taken, occur or be achieved.
Forward-looking information contained in this news release include,
but are not limited to, statements regarding the Company's ability
to complete the studies proposed for the grant award. In respect of
the forward-looking information contained herein, the Company has
provided such statements and information in reliance on certain
assumptions that management believed to be reasonable at the
time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including those risks
discussed in the Company's Annual Information Form dated July 27,
2021 (which may be viewed on the Company's profile at www.sedar.com) and the Company's Form 40-F,
Amendment No, 1 dated September 28, 2021 (which may be viewed on
the Company's profile at www.sec.gov). Furthermore, there can be no assurance
that the pending patent applications will issue as patents and that
challenges will not be instituted against the validity or
enforceability of such patents. Should one or more of these risks
or uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. Accordingly, readers should not place undue
reliance on forward-looking information contained in this news
release.
The forward-looking statements contained in this news release
are made as of the date of this release and, accordingly, are
subject to change after such date. The Company does not assume any
obligation to update or revise any forward-looking statements,
whether written or oral, that may be made from time to time by us
or on our behalf, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
ImmunoPrecise Antibodies (TSXV:IPA)
Historical Stock Chart
From Oct 2024 to Nov 2024
ImmunoPrecise Antibodies (TSXV:IPA)
Historical Stock Chart
From Nov 2023 to Nov 2024
